Cogent Biosciences: director Karen Jean Ferrante received 759 shares

What happened Karen Jean Ferrante, a director, received a grant of 759 derivative shares (transaction code A) at an acquisition price of $0.00, total value $0, reported on Oct 1, 2026.

Key details

• Transaction date and price: Oct 1, 2026 @ $0.00 per share.
• Shares acquired: 759 shares (derivative award).
• Shares owned after the transaction: not reported in the provided filing.
• Footnote: the filing states the option award was issued to the reporting person, who elected to take shares in lieu of cash compensation for services as a director pursuant to the issuer's non-employee director compensation plan; the number of options granted was determined by dividing the cash compensation otherwise payable for the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
• Filing date and report period: filed Oct 5, 2026; period of report Oct 1, 2026. Filing timeliness is not indicated in the provided information.

Why it may matter This was an option award issued in lieu of cash compensation under the non-employee director compensation plan; it is not a market purchase or sale. A filing does not show why the insider traded or why the company acted.